Selank vs Semax
A side-by-side research comparison of Selank and Semax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Selank | Semax |
|---|---|---|
| Full name | Selank (TP-7) | Semax (ACTH 4-10 analog) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Modulates GABA-A allosteric sites, increases BDNF, stabilizes enkephalin degradation, and influences serotonin metabolism. Enhances IL-6 and Th1/Th2 balance. | Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity. |
| Molecular weight | 751.9 Da | 813.9 Da |
| Half-life | 3-5 min (IV) / 15-30 min (intranasal) | 3-5 min (systemic) / extended (intranasal) |
| Bioavailability | Moderate (intranasal) | Moderate (intranasal) |
| Typical dose | 250-750 mcg per spray dose | 200-600 mcg per dose |
| Frequency | 2-3x daily | 2-3x daily |
| Route | Intranasal spray | Intranasal drops/spray |
Selank reported benefits
- Anxiolytic without sedation
- Improved memory/learning
- Cognitive flexibility
- Immune modulation
- BDNF upregulation
- No addiction
Semax reported benefits
- Enhanced attention/focus
- Memory improvement
- Neuroprotection (stroke)
- BDNF/NGF upregulation
- Improved learning
- Optic nerve support
Related comparisons
Research and educational reference only. Not medical advice.